nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

23.04.2019 | Editorial Commentary

Time for new imaging and therapeutic approaches in cardiac amyloidosis

verfasst von: Riemer H. J. A. Slart, Andor W. J. M. Glaudemans, Walter Noordzij, Johan Bijzet, Bouke P. C. Hazenberg, Hans L. A. Nienhuis

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Excerpt

Cardiac amyloidosis (CA), commonly resulting from deposition of misfolded immunoglobulin light chain (AL) or transthyretin (ATTR) protein, is an underestimated cause of heart failure [1, 2]. ATTR has gained increasing attention in recent years and can be divided into a hereditary type (ATTRv) and a wild-type (ATTRwt) [3]. Diagnosis of CA is frequently delayed for several reasons [4]. Clinical manifestations are varied, serum cardiac biomarker elevation is non-specific, awareness of CA is lacking, and noninvasive techniques for specific diagnosis became only more recently available. In patients with heart failure with preserved ejection fraction (HFpEF), moderate or severe interstitial amyloid deposition is present in 5–13% of the cases, while mild interstitial and/or intramural coronary vascular deposition was present in 12% [2, 5]. …

Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135:1357–77.CrossRefPubMedPubMedCentral

Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–94.CrossRefPubMed

Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25:215–9.CrossRefPubMed

Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the amyloidosis. Research consortium. Adv Ther. 2015;32:920–8.CrossRefPubMedPubMedCentral

Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2:113–22.CrossRefPubMedPubMedCentral

Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70:466–77.CrossRefPubMed

Hazenberg BP, van Rijswijk MH, Piers DA, Lub-de Hooge MN, Vellenga E, Haagsma EB, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med. 2006;119:355.e15–24.CrossRef

Biancalana M, Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta. 2010;1804:1405–12.CrossRefPubMedPubMedCentral

Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol. 2016;25:413–7.CrossRefPubMed

10.

Ng QKT, Sethi P, Saunders TA, Pampaloni MH, Flavell RR. Discordant findings on 18F-NaF and 99mTc-HDP bone scans in a patient with ATTR cardiac amyloidosis. Clin Nucl Med. 2018;43:e89–92.CrossRefPubMed

11.

Susuki S, Ando Y, Sato T, Nishiyama M, Miyata M, Suico MA, et al. Multi-elemental analysis of serum and amyloid fibrils in familial amyloid polyneuropathy patients. Amyloid. 2008;15:108–16.CrossRefPubMed

12.

Morton KA. Extra-skeletal uptake of bone agents. J Nucl Med Technol. 1999;27:51–3.PubMed

13.

Nakanishi T, Yoshioka M, Moriuchi K, Yamamoto D, Tsuji M, Takubo T. S-sulfonation of transthyretin is an important trigger step in the formation of transthyretin-related amyloid fibril. Biochim Biophys Acta. 2010;1804:1449–56.CrossRefPubMed

14.

Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med. 1995;22:1393–401.CrossRefPubMed

15.

Cardoso I, Pereira PJ, Damas AM, Saraiva MJ. Aprotinin binding to amyloid fibrils. Eur J Biochem. 2000;267:2307–11.CrossRefPubMed

16.

Jonker DL, Hazenberg BP, Nienhuis HL, Slart RH, Glaudemans AW, Noordzij W. Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: a marker for neuropathy or cardiomyopathy in case of heart failure? J Nucl Cardiol. 2018. https://doi.org/10.1007/s12350-018-01477-y

17.

Kircher M, Ihne S, Brumberg J, Morbach C, Knop S, Kortüm KM, et al. Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imag. 2019. https://doi.org/10.1007/s00259-019-04290-y

18.

Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54:213–20.CrossRefPubMed

19.

Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using 18Fflorbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41:1652–62.CrossRefPubMed

20.

Manwani R, Page J, Lane T, Burniston M, Skillen A, Lachmann HJ, et al. A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement. Amyloid. 2018;25:247–52.CrossRefPubMed

21.

Park MA, Padera RF, Belanger A, Dubey S, Hwang DH, Veeranna V, et al. 18F-Florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. Circ Cardiovasc Imaging. 2015;8(8). https://doi.org/10.1161/CIRCIMAGING.114.002954

22.

Kim YJ, Ha S, Kim YI. Cardiac amyloidosis imaging with amyloid positron emission tomography: a systematic review and meta-analysis. J Nucl Cardiol. 2018. https://doi.org/10.1007/s12350-018-1365-x

23.

Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid. 2014;21:35–44.CrossRefPubMed

24.

Treglia G, Glaudemans AWJM, Bertagna F, Hazenberg BPC, Erba PA, Giubbini R, et al. Eur J Nucl Med Mol Imaging. 2018;45(11):1945–55.CrossRefPubMed

25.

Slart RHJA, Glaudemans AWJM, Hazenberg BPC, Noordzij W. Imaging cardiac innervation in amyloidosis. J Nucl Cardiol. 2019;26(1):174–87.CrossRefPubMed

26.

Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21.CrossRefPubMed

27.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31.CrossRefPubMed

28.

Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, et al. Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139:431–43.CrossRefPubMed

29.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–16.CrossRefPubMed

30.

Sekijima Y, Yazaki M, Oguchi K, Ezawa N, Yoshinaga T, Yamada M, et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology. 2016;87:773–81.CrossRefPubMed

31.

Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Palladini G, Merlini G, et al. Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. J Proteome Res. 2013;12:5642–55.CrossRefPubMed

32.

Di Silvestre D, Brambilla F, Mauri PL. Multidimensional protein identification technology for direct-tissue proteomics of heart. Methods Mol Biol. 2013;1005:25–38.CrossRefPubMed

Titel: Time for new imaging and therapeutic approaches in cardiac amyloidosis
verfasst von: Riemer H. J. A. Slart
Andor W. J. M. Glaudemans
Walter Noordzij
Johan Bijzet
Bouke P. C. Hazenberg
Hans L. A. Nienhuis
Publikationsdatum: 23.04.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04325-4

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

TSH suppression aggravates arterial inflammation — an 18F-FDG PET study in thyroid carcinoma patients

Breaking an unhelpful circle, where innovation and regularia delay clinical practice for patient benefit

PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy

Clinical utility of 68Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma

Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections

Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?